Sirona Biochem Announces Cfda Approval Of Sglt2 Inhibitor For Phase I Clinical Trial | Latest News RSS feed

Sirona Biochem Announces Cfda Approval Of Sglt2 Inhibitor For Phase I Clinical Trial - Latest News


Sirona Biochem Announces CFDA Approval of SGLT2 Inhibitor for Phase I Clinical Trial

July 12, 2018 08:00 ET | Source: Sirona Biochem Corp. VANCOUVER, British Columbia, July 12, 2018 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V:SBM) (FSE:ZSB) (the “Company”) announced today that par... read more

Sirona Biochem Announces Results of AGM & CEO Update

VANCOUVER, BC--(Marketwired - December 19, 2017) - Sirona Biochem Corp. (TSX VENTURE: SBM) (ZSB.F) (ZSB.DE) (the "Company") announces that all ... months to approve the filing. Approval for the Phase ... read more

Sirona Biochem : Announces SGLT2 IND Submission Milestone

With acceptance of the IND application by the CFDA, Fosun Pharma will begin clinical trials, triggering another milestone payment to Sirona Biochem. "We are very pleased with the progress that has bee... read more

Looking for another news?


Sirona Biochem Announces Receipt of $500,000 US Milestone Payment

VANCOUVER, BC--(Marketwired - January 29, 2018) - Sirona Biochem Corp. (TSX VENTURE ... China Food and Drug Administration (CFDA) approval of the IND filing, which will lead to a clinical trial of Sir... read more


Sirona Biochem : Announces Results of AGM & CEO Update

A successful clinical trial will yield compelling scientific data which will further increase the value and marketability of the compound. Kevin will be part of the Sirona Biochem team attending ... L... read more

Sirona Biochem Announces Results of AGM & CEO Update

VANCOUVER, BC--(Marketwired - December 19, 2017) - Sirona Biochem Corp. (TSX VENTURE: SBM) (ZSB.F) (ZSB.DE) (the "Company") announces that all ... months to approve the filing. Approval for the Phase ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us